Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | KIT D419del |
Gene Variant Detail | |
Relevant Treatment Approaches | KIT Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
KIT D419del | hematologic cancer | no benefit | Crenolanib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing KIT D419del did not respond to treatment with Crenolanib in culture (PMID: 31182436). | 31182436 | |
KIT D419del | hematologic cancer | no benefit | KIT Inhibitor | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing KIT D419del did not respond to treatment with Sprycel (dasatinib) in culture (PMID: 31182436). | 31182436 |
KIT D419del | mastocytosis | predicted - sensitive | KIT Inhibitor | Imatinib | Case Reports/Case Series | Actionable | In a clinical case study, Gleevec (imatinib) treatment resolved symptoms and stopped disease progression after 32 months in a pediatric patient with progressive cutaneous mastocytosis harboring a somatic KIT D419del and a germline S840N mutation (PMID: 18567837). | 18567837 |
KIT D419del | Advanced Solid Tumor | predicted - sensitive | KIT Inhibitor | Imatinib | Preclinical - Biochemical | Actionable | In a preclinical study, Gleevec (imatinib) treatment inhibited Kit autophosphorylation in transformed cells expressing KIT D419del in culture (PMID: 16143141). | 16143141 |